Clivus chordoma

Summary

Clivus chordoma (MONDO:0003849) is a disease and 2 clinical trials. Top therapeutic interventions include afatinib. A subtype of skull base chordoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	clivus chordoma
Mondo ID	MONDO:0003849
DOID	DOID:6312
NCIT	C5412
SNOMED CT	446939001
UMLS	C1333071
MedGen	232372
GARD	0023692
Anatomy (UBERON)	UBERON:0004108
Is cancer (heuristic)	no

Also known as: chordoma (disease) of clivus of occipital bone · chordoma of clivus · chordoma of the clivus · clival chordoma · clivus of occipital bone chordoma (disease)

Data availability: 11 cell lines.

Disease family

This is a subtype of skull base chordoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › musculoskeletal system cancer › bone cancer › skull cancer › skull base chordoma › clivus chordoma

Subtypes (1): clivus chondroid chordoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05519917	PHASE2	UNKNOWN	Study to Evaluate the Efficacy of Afatinib in Skull Base Chordoma
NCT00931931	PHASE1	COMPLETED	HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
AFATINIB	4	1
CHEMBL2347958	0	1
CHEMBL4283673	0	1
CHEMBL4759112	0	1